DNMT1 and cardiac hypertrophy: Consistent with previously discussed studies regarding the therapeutic potential of DNMT inhibition, Stenzig et al. demonstrated that daily subcutaneous injections of 2 mg of a DNMT inhibitor, N-phthalyl-l-tryptophan (RG108), for 4 weeks partially rescued heart function and decreased cardiomyocyte DNA methylation in a transverse aortic constriction-induced rat model of cardiac hypertrophy [136].